uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
uniQure N.V. is conducting a primary offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share, for aggregate gross proceeds of $225,000,003. Underwriting discounts total $13,500,000, with estimated proceeds to uniQure before expenses of $211,500,003. Delivery is expected on June 25, 2026.
The underwriters have a 30-day option to purchase up to an additional 741,758 ordinary shares. After the offering (no exercise of the option), ordinary shares outstanding would be 67,978,304 (or 68,720,062 if the option is fully exercised). Proceeds are intended to fund commercialization readiness and potential launches for AMT-130, a confirmatory study for AMT-130, development of other clinical candidates, business development and general corporate purposes.
uniQure reports a Rule 144 notice to sell ordinary shares. The filing lists brokered sales activity and planned dispositions tied to vested PSUs/RSUs and option exercises. The filing shows multiple past sales by Matthew C. Kapusta on 06/17/2026 and 06/18/2026.
uniQure N.V. is offering $150,000,000 of ordinary shares and pre-funded warrants pursuant to a preliminary prospectus supplement dated June 22, 2026. The offering includes ordinary shares and, in lieu of shares to certain investors, pre-funded warrants exercisable at $0.0001 per share. Proceeds are intended to fund commercialization readiness and a confirmatory study for AMT-130, development of other clinical candidates, business development and general corporate purposes. The supplement summarizes recent clinical and regulatory developments for AMT-130, AMT-260 and AMT-191, including a three-year Phase I/II analysis for AMT-130 and planned BLA and UK MAA submissions in Q3 2026.
uniQure N.V.’s CEO and Managing Director Matthew C. Kapusta reported a combination of share sales and option exercises in uniQure N.V. ordinary shares. On June 17–18, 2026, he sold an aggregate of 206,100 ordinary shares in multiple open‑market transactions and exercised stock options covering 67,237 ordinary shares.
Sale prices were reported as weighted averages, with underlying trades occurring in ranges disclosed in the footnotes. The filing states these transactions were carried out under a Rule 10b5‑1 sales plan adopted on October 5, 2025. Following the transactions, Kapusta directly owned 521,795 ordinary shares, and the derivative section in this filing shows no remaining stock options related to these exercises.
uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. On June 17, 2026, he exercised stock options for 11,685 shares at strike prices of $19.39 and $31.71 per share.
The same total of 11,685 shares was then sold in open-market transactions at weighted average prices of $42.60, $43.66, and $47.08 per share. The filing states that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026.
uniQure N.V. director Jack Kaye exercised stock options and sold the resulting shares in a coordinated transaction. On June 17, 2026, he exercised options for 5,295 Ordinary Shares at $31.71 per share and then sold the same 5,295 shares in the open market at a weighted average price of $42.57, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
Following these transactions, Kaye directly holds 25,996 Ordinary Shares of uniQure. The exercised stock option, which vested in full on January 25, 2020 and had an expiration date of January 25, 2029, now shows zero remaining derivative balance.
uniQure N.V. reported preliminary six-month data from the first, low-dose cohort in its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. Three of six patients showed meaningful reductions in disabling seizures between months four and six, with declines of 79% to 100% from baseline.
The other three patients had mixed results, ranging from a 33% decrease to a 36% increase in disabling seizures over the same period. AMT-260 was generally well-tolerated, with no serious adverse events related to the therapy or surgery, only mild to moderate side effects such as headache, and no need for immunosuppression.
uniQure N.V. reported an insider sale filing indicating planned and recent dispositions of Ordinary Shares by Matthew C. Kapusta. The filing lists 41,671 shares associated with Citigroup Global Markets on 06/18/2026, 37,015 shares labeled "Vested Stock from PSU and RSU" to be sold on 06/18/2026, and a separate "Stock option exercise and sale" of 4,656 shares on 06/18/2026. The filing also records actual sales in the prior three months: 152,844 shares sold on 06/17/2026 for $6,724,136.05 and 11,585 shares sold on 06/18/2026 for $563,610.25.
UniQure N.V. reported Form 144 sales of Ordinary Shares on 06/17/2026 through Citigroup Global Markets. The filing lists 101,848 shares described as vested PSU/RSU sales pursuant to a Rule 10b5-1 plan and 62,581 shares from a stock option exercise and sale pursuant to a Rule 10b5-1 plan. The broker is Citigroup Global Markets and the transactions are marked as cash and compensation related.
uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. He exercised stock options for 10,000 shares at $8.49 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $27.85 per share. After these transactions, he directly holds 43,254 Ordinary Shares. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026, and that the sale prices ranged from $27.58 to $28.05.